S&CO Inc. Acquires New Position in Insmed, Inc. $INSM

S&CO Inc. acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 13,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,386,000.

Several other large investors have also bought and sold shares of the company. Norges Bank bought a new position in shares of Insmed in the fourth quarter worth approximately $506,625,000. RTW Investments LP grew its holdings in shares of Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after buying an additional 1,758,321 shares during the last quarter. Orbis Allan Gray Ltd bought a new stake in shares of Insmed during the second quarter valued at approximately $153,389,000. State Street Corp increased its position in shares of Insmed by 30.6% during the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after acquiring an additional 1,217,390 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Insmed by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after acquiring an additional 1,140,524 shares during the last quarter.

Insmed Stock Down 2.1%

INSM opened at $123.74 on Friday. The stock has a market capitalization of $27.02 billion, a price-to-earnings ratio of -30.11 and a beta of 0.81. The firm has a 50 day moving average price of $107.88 and a 200-day moving average price of $128.20. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter last year, the company posted ($1.70) earnings per share. The firm’s quarterly revenue was up 296.1% on a year-over-year basis. Equities research analysts forecast that Insmed, Inc. will post -1.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $175.00 price objective on shares of Insmed in a research report on Thursday, August 6th. Royal Bank Of Canada reduced their target price on Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a report on Friday, June 5th. HC Wainwright restated a “buy” rating on shares of Insmed in a research note on Monday, August 10th. Guggenheim lowered their price target on Insmed from $207.00 to $205.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $205.52.

Insider Transactions at Insmed

In related news, COO Roger Adsett sold 239,850 shares of Insmed stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer owned 98,744 shares of the company’s stock, valued at $13,159,612.88. The trade was a 70.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO William Lewis sold 21,398 shares of Insmed stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $103.32, for a total value of $2,210,841.36. Following the completion of the sale, the chief executive officer directly owned 258,917 shares of the company’s stock, valued at $26,751,304.44. The trade was a 7.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 294,440 shares of company stock valued at $37,758,548. Corporate insiders own 2.10% of the company’s stock.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.